secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcutis Biotherapeutics, Inc. (ARQT)
CIK:        0001787306
Form:       8-K
Filed at:   2024-02-27T23:59:59+00:00
Accession:  0001787306-24-000029
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcutis Q4 2023 revenue $13.5M (+357% YoY), net loss $66.3M; ZORYVE foam launched
--------------------------------------------------------------------------------

- Q4 net product revenue $13.5M vs $3.0M Q4 2022, driven by 67% sequential demand growth and GTN improvement.
- Full-year 2023 total revenue $59.6M (incl. $30.4M Huadong upfront); net loss $262.1M ($3.78/share).
- R&D expenses fell 39% to $110.6M; cash & securities $272.8M as of Dec 31, 2023.
- FDA approved ZORYVE foam for seborrheic dermatitis Dec 2023; launched Jan 2024.
- PDUFA target date July 7, 2024 for roflumilast cream 0.15% in atopic dermatitis.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787306/000178730624000029/0001787306-24-000029-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787306/000178730624000029/arqt-20240227.htm
  HTML page:      https://secwatch.observer/filing/0001787306-24-000029

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer